These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 19475867)

  • 1. [Experimental therapy in Duchenne muscular dystrophy].
    van den Bergen JC; Straathof CS; Aartsma-Rus A; Ginjaar IB; Verschuuren JJ
    Ned Tijdschr Geneeskd; 2009 May; 153(18):870-5. PubMed ID: 19475867
    [No Abstract]   [Full Text] [Related]  

  • 2. 128th ENMC International Workshop on 'Preclinical optimization and Phase I/II Clinical Trials Using Antisense Oligonucleotides in Duchenne Muscular Dystrophy' 22-24 October 2004, Naarden, The Netherlands.
    Muntoni F; Bushby K; van Ommen G
    Neuromuscul Disord; 2005 Jun; 15(6):450-7. PubMed ID: 15907292
    [No Abstract]   [Full Text] [Related]  

  • 3. Antisense oligonucleotides in the treatment of Duchenne muscular dystrophy: Where are we now?
    Wilton SD; Fletcher S
    Neuromuscul Disord; 2005 Jun; 15(6):399-402. PubMed ID: 15907285
    [No Abstract]   [Full Text] [Related]  

  • 4. New insights in gene-derived therapy: the example of Duchenne muscular dystrophy.
    Aartsma-Rus A; den Dunnen JT; van Ommen GJ
    Ann N Y Acad Sci; 2010 Dec; 1214():199-212. PubMed ID: 21121926
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Molecular therapy for duchenne muscular dystrophy].
    Takeshima Y
    Nihon Rinsho; 2005 Dec; 63 Suppl 12():626-31. PubMed ID: 16416864
    [No Abstract]   [Full Text] [Related]  

  • 6. Gene therapy for Duchenne muscular dystrophy.
    Verhaart IE; Aartsma-Rus A
    Curr Opin Neurol; 2012 Oct; 25(5):588-96. PubMed ID: 22892952
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Treatment of Duchenne muscular dystrophy by induction of skipping of dystrophi exon].
    Matsuo M; Yagi M; Takeshima Y
    Rinsho Shinkeigaku; 2006 Nov; 46(11):936-8. PubMed ID: 17432225
    [No Abstract]   [Full Text] [Related]  

  • 8. Gene therapy progress and prospects: Duchenne muscular dystrophy.
    Foster K; Foster H; Dickson JG
    Gene Ther; 2006 Dec; 13(24):1677-85. PubMed ID: 17066097
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 149th ENMC International Workshop and 1st TREAT-NMD Workshop on: "planning phase i/ii clinical trials using systemically delivered antisense oligonucleotides in duchenne muscular dystrophy".
    Muntoni F; Bushby KD; van Ommen G
    Neuromuscul Disord; 2008 Mar; 18(3):268-75. PubMed ID: 18207401
    [No Abstract]   [Full Text] [Related]  

  • 10. In vivo comparison of 2'-O-methyl phosphorothioate and morpholino antisense oligonucleotides for Duchenne muscular dystrophy exon skipping.
    Heemskerk HA; de Winter CL; de Kimpe SJ; van Kuik-Romeijn P; Heuvelmans N; Platenburg GJ; van Ommen GJ; van Deutekom JC; Aartsma-Rus A
    J Gene Med; 2009 Mar; 11(3):257-66. PubMed ID: 19140108
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Myodys, a full-length dystrophin plasmid vector for Duchenne and Becker muscular dystrophy gene therapy.
    Duan D
    Curr Opin Mol Ther; 2008 Feb; 10(1):86-94. PubMed ID: 18228186
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gene therapy: the 'pro-sense' approach to Duchenne muscular dystrophy.
    van Deutekom JC
    Eur J Hum Genet; 2005 May; 13(5):518-9. PubMed ID: 15714219
    [No Abstract]   [Full Text] [Related]  

  • 13. Genetics. Hopping to a better protein.
    Pennisi E
    Science; 2008 Dec; 322(5907):1454-5. PubMed ID: 19056949
    [No Abstract]   [Full Text] [Related]  

  • 14. Exon skipping, a therapy for Duchenne muscular dystrophy. Interview by Guenter Scheuerbrandt.
    Platenburg G
    Acta Myol; 2008 Oct; 27():69-73. PubMed ID: 19364065
    [No Abstract]   [Full Text] [Related]  

  • 15. Gene therapy for duchenne muscular dystrophy: expectations and challenges.
    Rodino-Klapac LR; Chicoine LG; Kaspar BK; Mendell JR
    Arch Neurol; 2007 Sep; 64(9):1236-41. PubMed ID: 17846262
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effective rescue of dystrophin improves cardiac function in dystrophin-deficient mice by a modified morpholino oligomer.
    Wu B; Moulton HM; Iversen PL; Jiang J; Li J; Li J; Spurney CF; Sali A; Guerron AD; Nagaraju K; Doran T; Lu P; Xiao X; Lu QL
    Proc Natl Acad Sci U S A; 2008 Sep; 105(39):14814-9. PubMed ID: 18806224
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting RNA: an emerging hope for treating muscular dystrophy.
    Extance A
    Nat Rev Drug Discov; 2009 Dec; 8(12):917-8. PubMed ID: 19949390
    [No Abstract]   [Full Text] [Related]  

  • 18. Technology insight: therapy for Duchenne muscular dystrophy-an opportunity for personalized medicine?
    Lim LE; Rando TA
    Nat Clin Pract Neurol; 2008 Mar; 4(3):149-58. PubMed ID: 18268530
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development of antisense-mediated exon skipping as a treatment for duchenne muscular dystrophy.
    Heemskerk H; de Winter CL; van Ommen GJ; van Deutekom JC; Aartsma-Rus A
    Ann N Y Acad Sci; 2009 Sep; 1175():71-9. PubMed ID: 19796079
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical myology at the crossroads; the gospel truth.
    Dubowitz V
    Neuromuscul Disord; 2010 Feb; 20(2):95-6. PubMed ID: 20142012
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.